|Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors|
Y Jia, CH Yun, E Park, D Ercan, M Manuia, J Juarez, C Xu, K Rhee, ...
Nature 534 (7605), 129-132, 2016
|CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell ActivationCDK4/6 Inhibition Enhances the Antitumor T-cell Response|
J Deng, ES Wang, RW Jenkins, S Li, R Dries, K Yates, S Chhabra, ...
Cancer discovery 8 (2), 216-233, 2018
|Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer|
JP Robichaux, YY Elamin, Z Tan, BW Carter, S Zhang, S Liu, S Li, T Chen, ...
Nature medicine 24 (5), 638-646, 2018
|Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity|
K Vriens, S Christen, S Parik, D Broekaert, K Yoshinaga, A Talebi, ...
Nature 566 (7744), 403-406, 2019
|LKB1 loss links serine metabolism to DNA methylation and tumorigenesis|
F Kottakis, BN Nicolay, A Roumane, R Karnik, H Gu, JM Nagle, ...
Nature 539 (7629), 390-395, 2016
|Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4|
X Dai, W Gan, X Li, S Wang, W Zhang, L Huang, S Liu, Q Zhong, J Guo, ...
Nature medicine 23 (9), 1063-1071, 2017
|Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway|
KJ Kurppa, Y Liu, C To, T Zhang, M Fan, A Vajdi, EH Knelson, Y Xie, ...
Cancer cell 37 (1), 104-122. e12, 2020
|PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer|
B Diskin, S Adam, MF Cassini, G Sanchez, M Liria, B Aykut, C Buttar, E Li, ...
Nature immunology 21 (4), 442-454, 2020
|Induction of apoptosis in mouse liver by microcystin-LR|
T Chen, Q Wang, J Cui, W Yang, Q Shi, Z Hua, J Ji, P Shen
Molecular & Cellular Proteomics 4 (7), 958-974, 2005
|Single and Dual Targeting of Mutant EGFR with an Allosteric InhibitorSingle-agent Allosteric EGFR Inhibitor|
C To, J Jang, T Chen, E Park, M Mushajiang, DJH De Clercq, M Xu, ...
Cancer discovery 9 (7), 926-943, 2019
|Profound tissue specificity in proliferation control underlies cancer drivers and aneuploidy patterns|
LM Sack, T Davoli, MZ Li, Y Li, Q Xu, K Naxerova, EC Wooten, ...
Cell 173 (2), 499-514. e23, 2018
|RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer|
W Wang, JM Marinis, AM Beal, S Savadkar, Y Wu, M Khan, PS Taunk, ...
Cancer cell 34 (5), 757-774. e7, 2018
|CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer|
H Zhang, CL Christensen, R Dries, MG Oser, J Deng, B Diskin, F Li, Y Pan, ...
Cancer cell 37 (1), 37-54. e9, 2020
|Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target|
T Chen, D Ozel, Y Qiao, F Harbinski, L Chen, S Denoyelle, X He, ...
Nature Chemical Biology 7 (9), 610-616, 2011
|Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity|
JP Robichaux, YY Elamin, RSK Vijayan, MB Nilsson, L Hu, J He, F Zhang, ...
Cancer Cell 36 (4), 444-457. e7, 2019
|SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling|
C Fedele, S Li, KW Teng, CJR Foster, D Peng, H Ran, P Mita, MJ Geer, ...
Journal of Experimental Medicine 218 (1), e20201414, 2020
|Small-molecule targeting of brachyury transcription factor addiction in chordoma|
T Sharifnia, MJ Wawer, T Chen, QY Huang, BA Weir, A Sizemore, ...
Nature medicine 25 (2), 292-300, 2019
|Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with OsimertinibTargeting HER2 with Osimertinib in NSCLC|
S Liu, S Li, J Hai, X Wang, T Chen, MM Quinn, P Gao, Y Zhang, H Ji, ...
Clinical Cancer Research 24 (11), 2594-2604, 2018
|In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung AdenocarcinomaAsf1a Regulates Sensitivity to Immune-Checkpoint Therapy|
F Li, Q Huang, TA Luster, H Hu, H Zhang, WL Ng, A Khodadadi-Jamayran, ...
Cancer discovery 10 (2), 270-287, 2020
|CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma|
J Zhou, Z Wu, G Wong, E Pectasides, A Nagaraja, M Stachler, H Zhang, ...
Nature communications 8 (1), 13897, 2017